Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells.

Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, Clarke R.

Nat Rev Cancer. 2011 Jun 16;11(7):523-32. doi: 10.1038/nrc3081. Review.

2.

Live or let die: oestrogen regulation of survival signalling in endocrine response.

Butt AJ, Sutherland RL, Musgrove EA.

Breast Cancer Res. 2007;9(5):306. Review.

3.
4.

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.

Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.

Clin Cancer Res. 2005 Jul 15;11(14):5319-28.

5.
6.

Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.

Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC.

Eur J Cancer. 2012 Dec;48(18):3488-98. doi: 10.1016/j.ejca.2012.04.020. Epub 2012 Jun 2.

7.

Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Craig Jordan V, Lewis-Wambi J, Kim H, Cunliffe H, Ariazi E, Sharma CG, Shupp HA, Swaby R.

Breast. 2007 Dec;16 Suppl 2:S105-13. Epub 2007 Aug 24. Review.

8.

Estrogen-related cancer microenvironment of breast carcinoma.

Yamaguchi Y, Hayashi S.

Endocr J. 2009;56(1):1-7. Epub 2008 May 23. Review.

9.

Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.

Butt AJ, McNeil CM, Musgrove EA, Sutherland RL.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S47-59. Review.

10.
11.

Estrogen and cancer.

Liang J, Shang Y.

Annu Rev Physiol. 2013;75:225-40. doi: 10.1146/annurev-physiol-030212-183708. Epub 2012 Oct 8. Review.

PMID:
23043248
12.

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA.

Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8. Epub 2012 Jul 24.

13.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

14.

Estrogen receptor-mediated processes in normal and cancer cells.

Dickson RB, Stancel GM.

J Natl Cancer Inst Monogr. 2000;(27):135-45. Review.

PMID:
10963625
15.

Genes related to estrogen action in reproduction and breast cancer.

Basu A, Rowan BG.

Front Biosci. 2005 Sep 1;10:2346-72. Review.

PMID:
15970500
16.

Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer.

Patani N, Martin LA.

Mol Cell Endocrinol. 2014 Jan 25;382(1):683-94. doi: 10.1016/j.mce.2013.09.038. Epub 2013 Oct 9. Review.

PMID:
24121024
17.
18.

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.

Nicholson RI, McClelland RA, Robertson JF, Gee JM.

Endocr Relat Cancer. 1999 Sep;6(3):373-87. Review.

19.

Estrogens and breast cancer: present position.

Hawkins RA.

Scott Med J. 1980 Apr;25(2):152-7.

PMID:
7455674
20.

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.

Borley AC, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P, Nicholson RI.

Breast Cancer Res. 2008;10(6):R103. doi: 10.1186/bcr2206. Epub 2008 Dec 4.

Supplemental Content

Support Center